Auswahl der wissenschaftlichen Literatur zum Thema „Receptor, IGF Type 2“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Inhaltsverzeichnis
Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Receptor, IGF Type 2" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Zeitschriftenartikel zum Thema "Receptor, IGF Type 2"
Ballard, F. J., M. Ross, F. M. Upton und G. L. Francis. „Specific binding of insulin-like growth factors 1 and 2 to the type 1 and type 2 receptors respectively“. Biochemical Journal 249, Nr. 3 (01.02.1988): 721–26. http://dx.doi.org/10.1042/bj2490721.
Der volle Inhalt der QuelleRosenzweig, Steven A. „The Continuing Evolution of Insulin-like Growth Factor Signaling“. F1000Research 9 (23.03.2020): 205. http://dx.doi.org/10.12688/f1000research.22198.1.
Der volle Inhalt der QuelleBallard, F. J., L. C. Read, G. L. Francis, C. J. Bagley und J. C. Wallace. „Binding properties and biological potencies of insulin-like growth factors in L6 myoblasts“. Biochemical Journal 233, Nr. 1 (01.01.1986): 223–30. http://dx.doi.org/10.1042/bj2330223.
Der volle Inhalt der QuelleKim, Jane J., Byung-Chul Park, Yoshiaki Kido und Domenico Accili. „Mitogenic and Metabolic Effects of Type I IGF Receptor Overexpression in Insulin Receptor-Deficient Hepatocytes“. Endocrinology 142, Nr. 8 (01.08.2001): 3354–60. http://dx.doi.org/10.1210/endo.142.8.8332.
Der volle Inhalt der QuelleSchuller, A. G. P., J. W. van Neck, R. W. Beukenholdt, E. C. Zwarthoff und S. L. S. Drop. „IGF, type I IGF receptor and IGF-binding protein mRNA expression in the developing mouse lung“. Journal of Molecular Endocrinology 14, Nr. 3 (Juni 1995): 349–55. http://dx.doi.org/10.1677/jme.0.0140349.
Der volle Inhalt der QuelleWestwood, M. „THE IGF AXIS AT THE FETO-MATERNAL INTERFACE“. Reproductive Medicine Review 9, Nr. 3 (Oktober 2001): 173–96. http://dx.doi.org/10.1017/s096227990100031x.
Der volle Inhalt der QuelleOguchi, S., W. A. Walker und I. R. Sanderson. „Differentiation and Polarity Alter the Binding of IGF‐I to Human Intestinal Epithelial (Caco‐2) Cells“. Journal of Pediatric Gastroenterology and Nutrition 20, Nr. 2 (Februar 1995): 148–55. http://dx.doi.org/10.1002/j.1536-4801.1995.tb11527.x.
Der volle Inhalt der QuelleShooter, G. K., B. Magee, M. A. Soos, G. L. Francis, K. Siddle und J. C. Wallace. „Insulin-like growth factor (IGF)-I A- and B-domain analogues with altered type 1 IGF and insulin receptor binding specificities“. Journal of Molecular Endocrinology 17, Nr. 3 (Dezember 1996): 237–46. http://dx.doi.org/10.1677/jme.0.0170237.
Der volle Inhalt der QuelleHauguel-de Mouzon, S., M. Louizeau und J. Girard. „Functional alterations of type I insulin-like growth factor receptor in placenta of diabetic rats“. Biochemical Journal 288, Nr. 1 (15.11.1992): 273–79. http://dx.doi.org/10.1042/bj2880273.
Der volle Inhalt der QuelleMannucci, Edoardo. „Insulin Therapy and Cancer in Type 2 Diabetes“. ISRN Endocrinology 2012 (14.11.2012): 1–12. http://dx.doi.org/10.5402/2012/240634.
Der volle Inhalt der QuelleDissertationen zum Thema "Receptor, IGF Type 2"
O'Reilly, Kathryn Elizabeth. „Integration of mtor and IGF-1 signaling : feedback upregulation of survival pathways in human cancer cells /“. Access full-text from WCMC:, 2007. http://proquest.umi.com/pqdweb?did=1296100571&sid=11&Fmt=2&clientId=8424&RQT=309&VName=PQD.
Der volle Inhalt der QuelleLuey, Brendan Charles. „Targeting the type 1 IGF receptor in oestrogen-responsive breast cancer“. Thesis, University of Newcastle upon Tyne, 2013. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.709848.
Der volle Inhalt der QuelleGodefroy, Anastasia. „Nouvelle stratégie d'enzymothérapie substitutive ciblant le récepteur du mannose 6-phosphate pour les maladies lysosomales“. Thesis, Montpellier, 2019. http://www.theses.fr/2019MONTT030.
Der volle Inhalt der QuelleLysosomal diseases form a heterogeneous group of about fifty rare diseases. At present, only 9 lysosomal diseases have a specific treatment, mainly by enzyme replacement therapy but the beneficial effects appear often limited. The lack of targeting for the Mannose 6-Phosphate Receptor (M6PR), responsible for internalization into the lysosomes, would partly explain this moderate efficiency of the therapeutic enzymes. In this context, we have developed an innovative targeting approach based on Mannose 6-Phosphate Synthetic Analogues Functionalized at the Aglycone position (called AMFAs) to address the unmet needs of current treatments.The work of this thesis focuses mainly on Pompe disease which is a myopathy caused by the deficiency of a lysosomal enzyme, Acid Alpha Glucosidase (GAA), responsible for the conversion of glycogen into glucose. In order to improve the targeting of the therapeutic enzyme to lysosomes via the M6PR, we have functionalized the human recombinant GAA (rhGAA) with the AMFAs. Our studies on aged mice model of the adult form of the disease have demonstrated a significant increase of the enzyme internalization and for the first time, the restoration of muscle health and the significant improvement in motor function (article 1). We then investigated the properties of rhGAA-AMFA. We have proved that the effectiveness of rhGAA-AMFA is not only due to a better cell uptake but also to a more complete intracellular processing of the enzyme (article 2). Indeed, our results demonstrated that in myoblasts of patients affected by Pompe disease there is an overexpression of ACP2 and ACP5 acid phosphatases. These phosphatases can destroy the mannose 6-phosphate signal (M6P) naturally present on the enzyme, therefore possibly interrupting its processing into the active form. AMFA, unlike M6P, is insensitive to this degradation and thus ensures the stability of enzyme addressing in vitro, but also in vivo.All together, these results suggest that the grafting of the AMFAs on recombinant enzymes represents a new therapeutic solution for the treatment of Pompe disease and potentially for other lysosomal diseases
Vincent, Karla Kristine. „Transactivation of Beta 2 Adrenergic Receptor by Bradykinin type 2 Receptor via heterodimerization“. Diss., Georgia Institute of Technology, 2009. http://hdl.handle.net/1853/37117.
Der volle Inhalt der QuelleHower, Amy Elizabeth. „Receptor Functions of the Receptor-Type Protein Tyrosine Phosphatase PTPRO“. Scholarly Repository, 2008. http://scholarlyrepository.miami.edu/oa_dissertations/303.
Der volle Inhalt der QuellePatel, Dhaval Subhas. „Analysis of the daf-2 insulin/igf-1 receptor gene in Caenorhabditis elegans“. Thesis, University College London (University of London), 2006. http://discovery.ucl.ac.uk/1445066/.
Der volle Inhalt der QuelleHatcher-Solis, Candice N. „PHARMACOLOGICAL IMPLICATIONS OF ADENOSINE 2A RECEPTOR- DOPAMINE TYPE 2 RECEPTOR HETEROMERIZATION“. VCU Scholars Compass, 2016. http://scholarscompass.vcu.edu/etd/4458.
Der volle Inhalt der QuellePhillips, Timothy Trevor. „A study of metabotropic glutamate receptor type 2“. Thesis, University of Cambridge, 1999. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.624330.
Der volle Inhalt der QuelleDE, DOMENICO EMANUELA. „Role of type-2 cannabinoid receptor in reproduction“. Doctoral thesis, Università degli Studi di Roma "Tor Vergata", 2016. http://hdl.handle.net/2108/202948.
Der volle Inhalt der QuelleDaws, Michael Rory. „Hormone responsiveness in breast cancer cell growth : the role of the type I IGF receptor“. Thesis, University of Newcastle Upon Tyne, 1995. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.284225.
Der volle Inhalt der QuelleBücher zum Thema "Receptor, IGF Type 2"
Flavin, Nora. Cloning and characterisation of the bovine activin receptor type II gene (ActRII): Its localisation to chromosome 2 (BTA2) by somatic cell genetic analysis and the genotyping of an associated microsatelltie UCD2. Dublin: University College Dublin, 1996.
Den vollen Inhalt der Quelle findenInternational Symposium on Insulin Action and Its Disorders (1990 Ōtsu-shi, Japan). Recent advances in insulin action and its disorders: Proceedings of the International Symposium on Insulin Action and Its Disorders, Shiga, 16 May 1990. Herausgegeben von Shigeta Yukio 1929-, Kobayashi Masashi Dr und Olefsky Jerrold M. Amsterdam: Excerpta Medica, 1991.
Den vollen Inhalt der Quelle findenInternational Symposium on Molecular and Cellular Biology of Insulin and IGFs (3rd 1990 Gainesville, Fla.). Molecular biology and physiology of insulin and insulin-like growth factors. New York: Plenum Press, 1991.
Den vollen Inhalt der Quelle findenRainey, Susan. Cloning and characterization of the insulin receptor-related receptor (IRR) reveals that it is closely associated with trkA in the genome and maps to human chromosome 1q22, A type 2 diabetes susceptibility locus. 2002.
Den vollen Inhalt der Quelle findenLorent, Kristin. Expression of the Alpha-2-Macroglobulin Receptor System and the Amyloid Precursor Protein Family in Embryos and in Adult Brain of Wild Type and transg: Enic Mice (Acta Biomedica Lovaniensia , No 148). Coronet Books Inc, 1997.
Den vollen Inhalt der Quelle finden(Editor), Derek LeRoith, und Mohan K. Raizada (Editor), Hrsg. Molecular Biology and Physiology of Insulin and Insulin-Like Growth Factors (Advances in Experimental Medicine and Biology). Springer, 1991.
Den vollen Inhalt der Quelle findenZoccali, Carmine, Davide Bolignano und Francesca Mallamaci. Left ventricular hypertrophy in chronic kidney disease. Herausgegeben von David J. Goldsmith. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780199592548.003.0107_update_001.
Der volle Inhalt der QuelleNielsen, David A., Dmitri Proudnikov und Mary Jeanne Kreek. The Genetics of Impulsivity. Herausgegeben von Jon E. Grant und Marc N. Potenza. Oxford University Press, 2012. http://dx.doi.org/10.1093/oxfordhb/9780195389715.013.0080.
Der volle Inhalt der QuelleHohmann, Andrea G. Control of pain initiation by endogenous cannabinoids. Herausgegeben von Paul Farquhar-Smith, Pierre Beaulieu und Sian Jagger. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198834359.003.0033.
Der volle Inhalt der QuelleDilsizian, Vasken, Ines Valenta und Thomas H. Schindler. Myocardial Viability Assessment. Oxford University Press, 2015. http://dx.doi.org/10.1093/med/9780199392094.003.0021.
Der volle Inhalt der QuelleBuchteile zum Thema "Receptor, IGF Type 2"
Nissley, S. Peter. „Type 2 IGF Receptor-Mediated Events“. In The IGF System, 165–97. Totowa, NJ: Humana Press, 1999. http://dx.doi.org/10.1007/978-1-59259-712-3_8.
Der volle Inhalt der QuelleWerner, Haim. „Molecular Biology of the Type 1 IGF Receptor“. In The IGF System, 63–88. Totowa, NJ: Humana Press, 1999. http://dx.doi.org/10.1007/978-1-59259-712-3_4.
Der volle Inhalt der QuelleChernausek, Steven D., M. Jennifer Abuzzahab, Wieland Kiess, Doreen Osgood, Anke Schneider und Robert J. Smith. „IGF Resistance: The Role of the Type 1 IGF Receptor“. In Deciphering Growth, 121–30. Berlin, Heidelberg: Springer Berlin Heidelberg, 2005. http://dx.doi.org/10.1007/3-540-28902-x_10.
Der volle Inhalt der QuelleSheikh, Søren Paludan. „Angiotensin Type 2 Receptor“. In Encyclopedia of Signaling Molecules, 320–27. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-67199-4_451.
Der volle Inhalt der QuelleBiswas-Fiss, Esther E., Stephanie Affet, Malissa Ha, Takaya Satoh, Joe B. Blumer, Stephen M. Lanier, Ana Kasirer-Friede et al. „Angiotensin Type 2 Receptor“. In Encyclopedia of Signaling Molecules, 106–13. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4419-0461-4_451.
Der volle Inhalt der QuelleMoses, Alan C. „Insulin Resistance and Type 2 Diabetes mellitus: Is There a Therapeutic Role for IGF-1?“ In IGF-I and IGF Binding Proteins, 121–34. Basel: KARGER, 2005. http://dx.doi.org/10.1159/000085762.
Der volle Inhalt der QuelleSandhu, Manjinder S. „Insulin-Like Growth Factor-I and Risk of Type 2 Diabetes and Coronary Heart Disease: Molecular Epidemiology“. In IGF-I and IGF Binding Proteins, 44–54. Basel: KARGER, 2005. http://dx.doi.org/10.1159/000085755.
Der volle Inhalt der QuelleBiswas-Fiss, Esther E., Stephanie Affet, Malissa Ha, Takaya Satoh, Joe B. Blumer, Stephen M. Lanier, Ana Kasirer-Friede et al. „Angiotensin II Receptor Type 2“. In Encyclopedia of Signaling Molecules, 106. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4419-0461-4_100061.
Der volle Inhalt der Quellevan Roy, Frans, Volker Nimmrich, Anton Bespalov, Achim Möller, Hiromitsu Hara, Jacob P. Turowec, Nicole A. St. Denis et al. „C-Type Mannose Receptor 2“. In Encyclopedia of Signaling Molecules, 481. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4419-0461-4_100327.
Der volle Inhalt der QuelleGewies, Andreas, Jürgen Ruland, Alexey Kotlyarov, Matthias Gaestel, Shiri Procaccia, Rony Seger, Shin Yasuda et al. „Mannose Receptor, C-type 2“. In Encyclopedia of Signaling Molecules, 1042. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4419-0461-4_100743.
Der volle Inhalt der QuelleKonferenzberichte zum Thema "Receptor, IGF Type 2"
Bid, Hemant K., Doris Phelps und Peter J. Houghton. „Abstract 3277: Insulin-like growth factor-2 (IGF-2) circumvents the antiangiogenic activity of SCH717454, a human antibody that blocks ligand binding to the Type 1 insulin-like growth factor receptor (IGF-1R)“. In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-3277.
Der volle Inhalt der QuelleDelain, E., M. Barrav, J. Tapon-Bretaudière, F. Pochon und F. Van Leuven. „THE MOLECULAR ORGANIZATION OF HUMAN ALPHA 2-MACROGLOBULIN. AN IMMUNO ELECTRON MICROSCOPIC STUDY WITH MONOCLONAL ANTIBODIES“. In XIth International Congress on Thrombosis and Haemostasis. Schattauer GmbH, 1987. http://dx.doi.org/10.1055/s-0038-1643864.
Der volle Inhalt der QuelleZeng, X., D. Sachdev, H. Zhang und D. Yee. „Sequencing of type I IGF receptor (IGF1R) inhibition affects chemotherapy response in vitro and in vivo.“ In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-3122.
Der volle Inhalt der QuelleZanarel, Palomali, Marina Grigoli, Danielle de Oliveira, Patrícia Manzine und Márcia Cominetti. „IFG-1 PLASMA LEVELS ARE ALTERED IN PATIENTS WITH ALZHEIMER’S DIASEASE AND DIABTES MELLITUS TYPE 2“. In XIII Meeting of Researchers on Alzheimer's Disease and Related Disorders. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1980-5764.rpda045.
Der volle Inhalt der QuelleGoldblatt, D. L., A. Fouts, G. Valverde-Ha, M. Martinez-Moczygemba, D. Huston, M. J. Tuvim, B. F. Dickey und S. E. Evans. „Aerosolized Toll-Like Receptor Agonists Modulate Type 2 Allergic Inflammation“. In American Thoracic Society 2021 International Conference, May 14-19, 2021 - San Diego, CA. American Thoracic Society, 2021. http://dx.doi.org/10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a1347.
Der volle Inhalt der QuelleGalet, Colette, Ashley Gray, R. James Barnard, Brandon Castor, Junxiang Wan, Jonathan Said, Pedro Beltran, Franck Calzone, Pinchas Pinchas Cohen und William J. Aronson. „Abstract LB-458: Additive effects of caloric restriction and IGF-I receptor blockade on the progression of 22RV1 prostate cancer xenografts“. In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-lb-458.
Der volle Inhalt der QuelleKertels, O., M. Breun, H. Hänscheid, M. Kircher, P. Hartrampf, A. Schirbel, CM Monoranu et al. „Peptide Receptor Radionuclide Therapy in Patients with Neurofibromatosis Type 2 – Initial Experience“. In NuklearMedizin 2020. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1708361.
Der volle Inhalt der QuelleBoss, M., L. Deden, M. Brom, S. van Lith und M. Gotthardt. „Pituitary GLP-1 receptor expression in the pathophysiology of type 2 diabetes“. In NuklearMedizin 2019. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1683647.
Der volle Inhalt der QuelleAdachi, Yasushi, Hiroyuki Yamamoto, Masanori Ii, Hua Li, Hirokazu Ohashhi, Yoshiaki Arimura, Takao Endo, Kohzoh Imai, David P. Carbone und Yasushisa Shinomura. „Abstract 632: The efficacy of IGF-I receptor monoclonal antibody for human gastrointestinal carcinomas is independent for mutation status of k-ras“. In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-632.
Der volle Inhalt der QuelleDaigle, Noelle, Thomas G. Knapp, Suzann Duan, David W. Jones, Ali Azhdarinia, Sukhen C. Ghosh, Solmaz AghaAmiri et al. „Combined multiphoton microscopy and somatostatin receptor type 2 imaging of pancreatic neuroendocrine tumors“. In Multimodal Biomedical Imaging XVIII, herausgegeben von Fred S. Azar, Xavier Intes und Qianqian Fang. SPIE, 2023. http://dx.doi.org/10.1117/12.2648113.
Der volle Inhalt der QuelleBerichte der Organisationen zum Thema "Receptor, IGF Type 2"
Funkenstein, Bruria, und Cunming Duan. GH-IGF Axis in Sparus aurata: Possible Applications to Genetic Selection. United States Department of Agriculture, November 2000. http://dx.doi.org/10.32747/2000.7580665.bard.
Der volle Inhalt der QuellePlymate, Stephen R. Therapy of Prostate Cancer Using a Human Antibody Targeting the Type 1 Insulin-Like Growth Factor Receptor (IGF-IR). Fort Belvoir, VA: Defense Technical Information Center, September 2009. http://dx.doi.org/10.21236/ada524529.
Der volle Inhalt der QuelleMeidan, Rina, und Robert Milvae. Regulation of Bovine Corpus Luteum Function. United States Department of Agriculture, März 1995. http://dx.doi.org/10.32747/1995.7604935.bard.
Der volle Inhalt der QuelleZhuo, Chuanjun, Hongjun Tian, Lina Wang, Xiangyang Gao, Li Ding und Ming Liu. Comparative safety of glucagon like peptide‑1 receptor agonists in patients with type 2 diabetes: a network meta-analysis of cardiovascular outcome trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, August 2020. http://dx.doi.org/10.37766/inplasy2020.8.0122.
Der volle Inhalt der QuelleMeidan, Rina, und Joy Pate. Roles of Endothelin 1 and Tumor Necrosis Factor-A in Determining Responsiveness of the Bovine Corpus Luteum to Prostaglandin F2a. United States Department of Agriculture, Januar 2004. http://dx.doi.org/10.32747/2004.7695854.bard.
Der volle Inhalt der QuelleHansen, Peter J., und Amir Arav. Embryo transfer as a tool for improving fertility of heat-stressed dairy cattle. United States Department of Agriculture, September 2007. http://dx.doi.org/10.32747/2007.7587730.bard.
Der volle Inhalt der QuelleDeo, Salil, David McAllister, Naveed Sattar und Jill Pell. The time-varying cardiovascular benefits of glucagon like peptide-1 agonist (GLP-RA)therapy in patients with type 2 diabetes mellitus: A meta-analysis of multinational randomized trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, Juli 2021. http://dx.doi.org/10.37766/inplasy2021.7.0097.
Der volle Inhalt der QuelleZhang, Mingzhu, Wujisiguleng Bao, Luying Sun, Zhi Yao und Xiyao Li. Efficacy and safety of finerenone in chronic kidney disease associated with type 2 diabetes: meta-analysis of randomized clinical trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, März 2022. http://dx.doi.org/10.37766/inplasy2022.3.0020.
Der volle Inhalt der Quelleyu, luyou, jinping yang, xi meng und yanhua lin. Effectiveness of the gut microbiota-bile acid pathway (BAS) in the treatment of Type 2 diabetes: A protocol for systematic review and meta analysis. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, Juli 2022. http://dx.doi.org/10.37766/inplasy2022.7.0117.
Der volle Inhalt der QuelleSisler, Edward C., Raphael Goren und Akiva Apelbaum. Controlling Ethylene Responses in Horticultural Crops at the Receptor Level. United States Department of Agriculture, Oktober 2001. http://dx.doi.org/10.32747/2001.7580668.bard.
Der volle Inhalt der Quelle